论文部分内容阅读
[目的]评价中山大学肿瘤防治中心治疗儿童青少年霍奇金病(HD)的远期疗效 ,探讨合理治疗策略。[方法]回顾性分析采用MOPP或ABVD方案或两方案交替加或不加放疗的治疗方法治疗66例4岁～18岁HD的远期疗效。用Kaplan_Meier法计算全组生存率 ,比较单纯化疗与化疗联合放疗的生存率、Ⅰ～Ⅱ A 期和Ⅱ B～Ⅳ B 期患者生存率的差别。[结果]全组66例病人 ,中位随访7.5年(1至19.6年) ,3年总生存率91.83% ;5年总生存率88.23%,10年总生存率83.57 % ,15年总生存率71.94%。Ⅰ～Ⅱ A 期28例,10年总生存率96.15%;Ⅱ B～Ⅳ B 期38例,10年总生存率76.17 %;有显著统计学差异(P=0.0436)。单用化疗组10年总生存率83.63%,化疗 +放疗组10年总生存率84.15 % ,无统计学差异(P=0.8569)。[结论]对儿童青少年HD ,采用MOPP或ABVD方案或联合放疗 ,可获得80%以上治愈率 ,早期治愈率比晚期高。单用化疗与化疗 +放疗远期生存率无差别
[Objective] To evaluate the long-term efficacy of Sun Yat-sen University Cancer Center in the treatment of Hodgkin’s disease (HD) in children and adolescents and to explore the reasonable treatment strategy. [Methods] The long-term results of 66 cases of 4-year-old to 18-year-old HD patients treated with MOPP or ABVD regimen or two regimens with or without radiotherapy were retrospectively analyzed. The Kaplan-Meier method was used to calculate the overall survival rate. Survival rates of patients treated with chemotherapy and chemotherapy combined with radiotherapy were compared. Survival rates of patients in stage Ⅰ ~ Ⅱ A and Ⅱ B ~ Ⅳ B were compared. [Results] All patients were followed up for a median of 7.5 years (ranged from 1 to 19.6 years) with a median follow-up of 91.83%. The overall 5-year survival rate was 88.23%, the 10-year overall survival rate was 83.57%, and the 15-year overall survival rate 71.94%. There were 28 cases of stage Ⅰ ~ Ⅱ A with a 10-year overall survival rate of 96.15%. 38 cases of stage Ⅱ B-Ⅳ B had a 10-year overall survival rate of 76.17%. There was a statistically significant difference (P = 0.0436). The 10-year overall survival rate was 83.63% in the chemotherapy alone group, and the 10-year overall survival rate was 84.15% in the chemotherapy plus radiotherapy group, with no significant difference (P = 0.8569). [Conclusion] For children and adolescents HD, the cure rate of more than 80% can be obtained with MOPP or ABVD regimen or combined radiotherapy, and the early cure rate is higher than that of the late stage. Single chemotherapy and chemotherapy + radiotherapy no difference in long-term survival